Trilantic Capital Partners Europe Acquires 90% in Doppel Farmaceutici
Summary
Private equity firm Trilantic Capital Partners Europe has completed the acquisition of a 90% shareholding in Doppel Farmaceutici, an Italian leader in pharmaceutical research, development, formulation, manufacturing and packaging.Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel.Trilantic Europe and Doppel’s management team aim to expand Doppel both organically and as a platform to acquire other players in the CDMO sector.Since 2003, the company has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.In 2009, Doppel launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.